A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

References

• Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25: 1916–1923
   PubMed Web of Science ®Google Scholar
• Maartense E, Hermans J, Kluin-Nelemans J C, Kluin P M, Van Deijk W A, Snijder S, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in the Netherlands. Ann Oncol 1998; 9: 1219–1227
   PubMed Web of Science ®Google Scholar
• Shipp M A, On behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Group. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994, On behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Group.
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphomas: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Ma D, Osterborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. Proc ASCO 2004; 22(14S)6500
   Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Green M. Anthracycline cardiotoxicity, no longer an issue?. Ann Oncol 1998; 9: 691–693
   PubMed Web of Science ®Google Scholar
• Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 277–281
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Meyer R M, Browman G P, Samosh M L, Benger A M, Bryant-Lukosius D, Wilson W E, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Sadava D, Coleman A, Kane S E. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res 2002; 12: 301–309
   PubMed Web of Science ®Google Scholar
• Gill P S, Wernz J, Scadden D T, Cohen P, Mukwaya G M, von Roenn J H, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353–2364
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poizot-Martin I, Saint-Marc T, Spano J P, Cacoub P. Phase IV study of liposomal daunorubicin (daunoxome) in AIDS-related Kaposi's sarcoma. Am J Clin Oncol 2002; 25: 57–59
   PubMed Web of Science ®Google Scholar
• Richardson D S, Kelsey S M, Johnson S A, Tighe M, Cavenagh J D, Newland A C. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15: 247–253
   PubMed Web of Science ®Google Scholar
• Flinn I W, Goodman S N, Post L, Jamison J, Miller C B, Gore S, et al. A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol 2000; 11: 691–695
   PubMed Web of Science ®Google Scholar
• McBride N C, Cavenagh J D, Ward M C, Grant I, Schey S, Gray A, et al. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 42: 89–98
   PubMed Web of Science ®Google Scholar
• Tulpule A, Rarick M U, Kolitz J, Bernstein J, Myers A, Buchanan L A, et al. Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 457–462
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Kantarjian H M, Cortes J, Thomas D A, Faderl S, Garcia-Manero G, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony-stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003; 97: 1711–1720
   PubMed Web of Science ®Google Scholar
• Mohrbacher A F, Gregory S A, Gabriel D A, Rusk J M, Giles F J. Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer 2002; 94: 2645–2652
   PubMed Web of Science ®Google Scholar
• Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994; 12: 103–110
   PubMed Web of Science ®Google Scholar
• O'Byrne K J, Thomas A L, Sharma R A. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002; 87: 15–20
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid malignancies: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Armitage J O, Potter J F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay J Y, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival – a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945–2953
   PubMed Web of Science ®Google Scholar
• Havlik R J, Yancik R, Long S, Ries L, Edwards B. The National Institute on Ageing and the National Cancer Institute SEER collaborative study on co-morbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74: 2101–2106
   PubMed Web of Science ®Google Scholar
• Dixon D O, Neilan B, Jones S E, Lipschitz D A, Miller T P, Grozea P N, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Lipshutz S, Colan S, Gelber R, Perez-atayde A R, Sallan S E, Sanders S P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–815
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao C S, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444–1454
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez A J, Cheson B D, Horning S J, Peterson B A, Carter W D, Varns C L, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol 2000; 11: 399–408
   PubMed Web of Science ®Google Scholar
• Martino R, Perea G, Caballero M D, Mateos M V, Ribera J M, de Oteyza J P, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisolone (CCOP) in elderly patients with diffuse large-cell lymphoma: results of a prospective phase II study. Haematologica 2002; 87: 822–827
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzalez M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-cell lymphoma. Med Oncol 2002; 19: 55–58
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari A L, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large cell lymphoma. Leuk Lymphoma 2006; 47: 2174–2180
   PubMed Web of Science ®Google Scholar